A close-up photograph of several cocoa beans in a woven basket. The beans are dark brown with a textured, wrinkled surface. The basket is made of light-colored, woven material. The background is a neutral, light color.

Cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood

Colloque Adebiotech – Modulation du stress oxydant – 1 juin 2016–
Pascale Fança-Berthon



MAINTENANCE OF ENDOTHELIAL FUNCTION AND ITS RELATION TO CARDIOVASCULAR HEALTH

Cardiovascular Disease (CVD)

CEREBROVASCULAR DISEASE


Ruptured plaques in the brain's arteries causes strokes with the potential for permanent brain damage.

Temporary blockages in an artery can also cause transient ischemic attacks (TIAs), which are warning signs of stroke; however, there is no brain injury.

PERIPHERAL ARTERY DISEASE

Narrowing in the arteries of the legs caused by plaque causes poor circulation.

This causes pain on walking and poor wound healing. Severe disease may lead to amputations.




CORONARY ARTERY DISEASE

Stable plaques in the heart's arteries cause angina (chest pain on exertion). Sudden plaque rupture and clotting causes heart muscle to die. This is a heart attack, or myocardial infarction.

What causes CVD? The Atherosclerosis process

Atherosclerosis causes arteries to narrow, weaken and be less flexible. It's the term for the process of fatty buildup in the inner lining of an artery. The buildup that results is called plaque and reduces the amount of blood and oxygen that is delivered to vital organs.





50%+

Cardiovascular disease (CVD) causes more than half of all deaths in Europe.¹



4 million

Number of deaths per year in Europe caused by cardiovascular disease (CVD) (1.9 million deaths in the EU).²



#1

CVD is the main cause of death in women in all countries of Europe and is the main cause of death in men in all but 6 countries.²



€196 billion

Overall estimated to yearly cost of CVD to the EU economy.²

BUT the major causes of chronic diseases are known, and if these risk factors were eliminated, at least 80% of all heart disease, stroke and type 2 diabetes would be prevented.¹

The major risk factors associated with cardiovascular health and coronary heart disease are:

- Physical inactivity
- Poor diet
- Alcohol abuse
- Smoking
- Obesity
- Diabetes
- **Hypertension (high blood pressure)**
- **High cholesterol**




Endothelial Function and CV health

The endothelium are the cells that line the entire circulatory system from the heart to the smallest capillaries. It plays multiple physiological roles:

- **Regulates smooth muscle tone => vasoconstriction/vasodilation**
- Hemostasis (= keep the blood within the vessel)
- Controls thrombosis => prothrombosis/antithrombosis
- Controls proliferation and inflammation
- Inhibits leucocyte and platelet cell adhesion

Endothelial cells secrete numerous vasoactive substances:

- **Vasodilators (NO, prostacyclin, endothelial derived hyperpolarizing factor)**
- Vasoconstrictor (Endothelin-1, angiotensin II and thromboxane)



Nature Reviews | Molecular Cell Biology

Endothelial dysfunction




can be defined as any phenotype in which this normal functional state is altered




recognized as the earliest identifiable event in the process of atherosclerosis



is associated with aging






Endothelial dysfunction and CVD



(Heiss et al, *Antioxidants & redox signaling*, 2015)

How can we assess endothelial function? ED-FMD

- Endothelial Dependent – Flow Mediated Dilation (ED-FMD) is a non-invasive method to measure vascular endothelial function
- used since 1992 (Celermajer et al.) and widely used (correlate well with invasive method)
- principle: induction of reactive hyperemia (increased blood flow following a period of transient brachial artery occlusion - 5 min) → induction of shear stress → increase in arterial diameter (= vasodilation) that is compared to baseline diameter
- mainly NO dependent (related to NO bioavailability)



FMD is predictor of future CVD

Significant inverse association between brachial FMD and future cardiovascular risk events

Increase in FMD of 1% is associated with a decrease in CVD risk

- **from 8%** (Ras et al, 2013; meta-analysis of **23 studies** with **14 753 subjects**)
- **to 12%** (Matsuzawa et al, 2015; meta-analysis of **35 studies** with **17 280 subjects**; see figure)

1 SD worsening in endothelial function is associated with doubled cardiovascular risk (Matsuzawa et al, 2015)



Dietary strategies aiming to improve endothelial function in healthy individuals are therefore important targets for the primary prevention of CVD.




Figure 4. Forest plot of adjusted risk ratio of FMD for cardiovascular events. CV indicates cardiovascular; FMD, flow-mediated dilation; RR, risk ratio.

(Matsuzawa et al, *J Am Heart Assoc*, 2015)



THE 13.5 CLAIM POSITIVE OPINIONS

“Cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow”



SCIENTIFIC OPINION

Scientific Opinion on the substantiation of a health claim related to cocoa flavanols and maintenance of normal endothelium-dependent vasodilatation pursuant to Article 13(5) of Regulation (EC) No 1924/2004¹

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)^{2,3}
European Food Safety Authority (EFSA), Parma, Italy

ABSTRACT


Following an application from Barry Callebaut Belgium an, submitted pursuant to Article 13(7) of Regulation (EC) No 1924/2004 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver its opinion on the scientific substantiation of a health claim related to cocoa flavanols and maintenance of normal endothelium-dependent vasodilatation. Cocoa flavanols are sufficiently characterised. The claimed effect to “help maintain endothelium-dependent vasodilatation which contributes to healthy blood flow”. The target population proposed by the applicant is the general healthy adult population. The Panel considers that consumption of cocoa flavanols may induce a beneficial physiological effect. In weighing the evidence, the Panel took into account that cocoa flavanols contained in EF products have been shown to increase blood flow significantly in the target population in one human intervention study, that in another study the effect was dose-dependent and occurred after one week of consumption, that the effect was supported by two additional studies, and that in one case observed in two out of three studies, a positive cellular physiological response to the coronary artery disease, although the mechanisms by which regular consumption of cocoa flavanols may induce a beneficial effect on blood flow are unclear. The Panel concludes that a cause and effect relationship has been established between the consumption of cocoa flavanols and maintenance of normal endothelium-dependent vasodilatation. The following wording reflects the scientific evidence: “Cocoa flavanols help maintain endothelium-dependent vasodilatation, which contributes to normal blood flow” in order to stress the claimed effect. 200 mg of cocoa flavanols should be consumed daily. This amount could be provided by 2.3 g of high-flavanol cocoa powder or 10 g of high-flavanol dark chocolate, both of which can be consumed in the course of a balanced diet. The target population is the general population. © European Food Safety Authority, 2015.

KEY WORDS

Cocoa flavanols, and endothelium-dependent vasodilatation, health claim.

- ✓ Information shall be given to the consumer that the beneficial effect is obtained with a daily intake of 200 mg of cocoa flavanols.
- ✓ The claim can be used only for cocoa beverages (with cocoa powder) or for dark chocolate which provide at least a daily intake of 200 mg of cocoa flavanols with a degree of polymerisation 1-10

What are cocoa flavanols?



(Goszcz et al, *Frontiers in Cardiovascular Medicine*, 2015)

The Health claim dossier

- 25 potentially pertinent publications – 4 published studies were used and discussed in the health claim application

EFSA concluded that:

- 1 study showed an effect on fasting ED-FMD after 12 weeks consumption of cocoa flavanols (Davison 2008)
- 1 study showed a dose dependent effect on fasting ED-FMD after one week of consumption (Grassi 2015)
- 2 additional studies (without proper control) were considered as supporting data (Grassi 2005 and 2008)

EFSA considered that the following studies provided supportive evidence:

- Patients with coronary artery disease (Balzer 2008 and Heiss 2010)
- Acute studies (Heiss 2007, Balzer 2008, Heiss 2003, Heiss 2005, Heiss 2007)
- Acute study/obese participants (Berry 2010)
- Acute healthy older adults (Monahan 2011)

Design: Randomized, double blind, placebo controlled, parallel.

Population: 49 Overweight and Obese adults

Site: Nutritional Physiology Research Centre at the University of South Australia

Dose: 902 mg flavanols + exercise, 902 mg flavanols w/o exercise, 36 mg flavanols + exercise, 36 mg flavanols w/o exercise

Duration: 12 weeks


Results: Compared to LF, HF increased FMD acutely (2 h post-dose) by 2.4% (P<0.01) and chronically (over 12 weeks; P<0.01) by 1.6%

ORIGINAL ARTICLE

Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects

K Davison^{1,2,3}, AM Coates^{2,3}, JD Buckley^{2,3} and PRC Howe^{2,3}

¹School of Molecular and Biomedical Sciences, University of Adelaide, Adelaide, South Australia, Australia; ²Nutritional Physiology Research Centre, School of Health Sciences, University of South Australia, Adelaide, South Australia, Australia and ³ATN Centre for Metabolic Fitness, School of Health Sciences, University of South Australia, Adelaide, South Australia, Australia



Element	Remarks
EFSA Opinion	Key Study
Improvements in FMD	Acute and Chronic, Significant and Clinically Relevant
Improvements in Blood Pressure	Significant (p < 0.05)

Design: Randomized, double blind, controlled, cross-over.

Population: 20 healthy volunteers

Dose: 0, 80, 200, 500 and 800mg cocoa flavanols/day in five periods lasting 1 week each

Duration: 1 week (treatment)

Results: Cocoa dose-dependently increased FMD from 6.2% (control) to 7.3, 7.6, 8.1 and 8.2% after the different flavanols doses, respectively ($P < 0.0001$).

Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals

Davide Grassi^a, Giovambattista Desideri^a, Stefano Necozone^a, Paolo di Giosia^a, Remo Barnabei^a, Leen Allegaert^b, Herwig Bernaert^b, and Claudio Ferri^a




FIGURE 2 Effects of cocoa on endothelium-dependent flow-mediated dilation in 20 healthy volunteers. Data are expressed as least square means with standard error of the mean. Data points with different superscripts are significantly different. Differences are considered significant when P value is less than 0.05.

Element	Remarks
EFSA Opinion	Key Study - proprietary
Improvements in FMD	Significant and Clinically Relevant with Clear Dose Response
Improvements in Blood Pressure	Significant ($p < 0.05$), with Clear Dose Response
Arterial stiffness	Dose response
Endothelin-1 (vasoconstrictor)	Dose response

Design: Randomized, double blind, controlled, cross-over.

Population: 20 essentially hypertensive and 15 control

Dose: 100 g per day Dark Chocolate (containing 88 mg flavanols) or 90 g per day flavanol-free white chocolate


Duration: 15 days (treatment)

Results: Hypertensives, FMD increased to almost normal values in the Dark Chocolate group vs. White Chocolate group ($p < 0.0001$)

Control, FMD increased in Dark Chocolate group vs. White Chocolate group ($p < 0.0001$)

Cocoa Reduces Blood Pressure and Insulin Resistance and Improves Endothelium-Dependent Vasodilation in Hypertensives

Davide Grassi, Stefano Necozione, Cristina Lippi, Giuseppe Croce, Letizia Valeri, Paolo Pasqualetti, Giovambattista Desideri, Jeffrey B. Blumberg, Claudio Ferri



Element	Remarks
EFSA Opinion	Supporting Study (Control)
Improvements in FMD	Significant and Clinically Relevant ($p > 0.0001$)
Improvements in Blood Pressure	BP vs. Baseline ($p > 0.0001$) SBP: -11.0 ± 6.3 mm Hg ($p < 0.0001$) DBP: -6.2 ± 4.2 mm Hg Ambulatory BP vs. Baseline ($p > 0.0001$) SBP: -11.9 ± 7.7 mm Hg ($p < 0.0001$) DBP: -8.5 ± 5.0 mm Hg ($p < 0.0001$)
LDL Cholesterol	Significant ($p > 0.05$)
Insulin sensitivity	Improvements in QUICKI and ISI

Design: Randomized, double blind, controlled, cross-over.

Population: 19 Hypertensives with Impaired Glucose Tolerance

Site: The Division of Internal Medicine and Centre of Hypertension and Cardiovascular Prevention Outpatient Unit

Dose: 100 mg flavonol rich dark chocolate (FRDC) bar and 100 mg flavonol free white chocolate (FFWC) bar

Duration: 1 week (treatment)

Results: FRDC ingestion significantly increased FMD ($p < 0.05$). FFWC did not affect vascular reactivity.

Element	Remarks
EFSA Opinion	Supporting Study (Control)
Improvements in FMD	Significant and Clinically Relevant ($p > 0.05$)
Improvements in Blood Pressure	BP: ($p < 0.0001$) SBP -3.82 +/- 2.40 mm Hg DBP -3.92 +/- 1.98 mm Hg Ambulatory BP SBP -4.52 +/- 3.94 mm Hg DBP -4.17 +/- 3.29 mm Hg
Cholesterol	-6.5% ($p < 0.0001$)
LDL Cholesterol	-7.5% ($p < 0.0001$)

Blood Pressure Is Reduced and Insulin Sensitivity Increased in Glucose-Intolerant, Hypertensive Subjects after 15 Days of Consuming High-Polyphenol Dark Chocolate¹⁻³

Davide Grassi,^{4*} Giovambattista Desideri,⁴ Stefano Necozione,⁴ Cristina Lippi,⁴ Raffaele Casale,⁴ Giuliana Properzi,⁴ Jeffrey B. Blumberg,⁵ and Claudio Ferri⁴

⁴Department of Internal Medicine and Public Health, University of L'Aquila, 67100 L'Aquila, Italy and ⁵Antioxidants Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111





FIGURE 3 Effect of FRDC (A) and FFWC (B) on FMD in IGT EH patients. Data are means \pm SD, $n = 19$. *Different from baseline and FFWC, $P < 0.05$.

Underlying mechanisms of the vasoprotective effects



HIGH-FLAVANOL COCOA EXTRACT: EXTENSION OF THE 13.5 CLAIM

“Cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow”



SCIENTIFIC OPINION

Scientific Opinion on the modification of the substantiation of a health claim related to cocoa flavanols and maintenance of normal endothelium-dependent vasodilation pursuant to Article 13(5) of Regulation (EC) No 1824/2006 following a request in accordance with Article 19 of Regulation (EC) No 1824/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)^{1,2}
European Food Safety Authority (EFSA), Parma, Italy


This scientific output, published on 22 July 2014, replaces the earlier version published on 03 May 2014

ABSTRACT

Following an application from Barry Callebaut Belgium NV, submitted pursuant to Article 19 of Regulation (EC) No 1824/2006 via the European Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the modification of the substantiation of a health claim related to “cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow”, pursuant to Article 13(5) of Regulation (EC) No 1824/2006. The modification concerns the extension of the substantiation of use of the claim to a high-flavanol (HF) cocoa extract to be consumed as separate addition or added to other foods, including beverages”, Cocoa flavanols, which are the subject of the health claim, have been traditionally characterised. Measurement of normal endothelium-dependent vasodilation is a validated physiological effect. The Panel concludes that a cause and effect relationship has been established between the consumption of cocoa flavanols in the HF cocoa extract (i.e. in capsules or tablets) and maintenance of normal endothelium-dependent vasodilation, in order to obtain the claimed effect. The mg of cocoa flavanols should be consumed daily. This amount could be provided by less than one gram of HF cocoa extract as capsule or tablet, and can be consumed in the context of a balanced diet. The target population is the general population.

- ✓ Information shall be given to the consumer that the beneficial effect is obtained with a daily intake of 200 mg of cocoa flavanols.
- ✓ The claim can be used only for cocoa beverages (with cocoa powder) or for dark chocolate which provide at least a daily intake of 200 mg of cocoa flavanols with a degree of polymerisation 1-10.
- ✓ The claim can be used only for capsules or tablets containing **high-flavanol cocoa extract which provide at least a daily intake of 200 mg of cocoa flavanols** with a degree of polymerisation 1-10.

ADME of flavanols



The acute effects of cocoa flavanols are mainly driven by monomers (epicatechin and catechin) and their metabolites

High-Flavanol cocoa extract pharmacokinetic study


Design: Randomized, partially blinded cross-over (5-day washout period)

Population: 6 healthy participants (3 men / 3 women)

Matrix & Dose: High-flavanol chocolate (460 mg flavanols), low-flavanol chocolate (60 mg flavanols), cocoa powder (459 mg flavanols), low-flavanol cocoa powder (27 mg flavanols), cocoa extract in capsules (449 mg flavanols)

Duration: one dose acute test + blood sampling before and during 6h after consumption (30, 60, 120, 240 and 360 min)

Endpoints: PK parameters on monomeric flavanols (epicatechin) – C_{max}, T_{max}, AUC



Formulation	C _{MAX} (µg.L ⁻¹)	T _{MAX} (min)	AUC (µg.L ⁻¹ .h)
High-flavanol chocolate	81.9 ± 5.7 ^a	60.0 ± 0.0	15317.2 ± 1200.1 ^a
low-flavanol chocolate	7.7 ± 2.0 ^b	108.0 ± 35.0	1186.5 ± 303.3 ^b
cocoa powder	151.1 ± 25.8 ^c	110.0 ± 28.6	27946.0 ± 4120.4 ^c
low-flavanol cocoa powder	7.4 ± 1.2 ^b	50.0 ± 6.3	959.6 ± 180.6 ^b
cocoa extract (caps)	119.6 ± 4.8 ^{ac}	100.0 ± 12.6	24614.1 ± 851.1 ^c

Cocoa flavanols consumed as a high-flavanol cocoa extract in capsules are as bioavailable as those contained in other matrices (dark chocolate and cocoa powder)

High-Flavanol cocoa extract patented process

- Unique patent-protected method for obtaining the high flavanol cocoa extract:
 - standardization to 29+% cocoa flavanols (AOAC method)
 - 23% of monomeric flavanols/total flavanols



- Convenient for nutraceuticals applications (effective quantity in caps)
- Advantage in comparison to classical cocoa matrices (low fat, low sugar) and regarding quantity of flavanols that could reasonably be consumed per day



HIGH-FLAVANOL COCOA EXTRACT: BEHIND THE CLAIM

*The case of blood pressure
reduction*

The up to date data

Cochrane review (Ried et al, 2012):

- 20 acute or short term chronic studies (mean 4.4 weeks, range 2-8 weeks, n=19, and one trial of 18 weeks)
- 856 adults with or without hypertension (mean systolic and diastolic blood pressure across control groups from 110 to 154 mm Hg and from 66 to 91.6 mm Hg respectively)
- daily intake : 30-1080 mg of flavanols (mean=545.5 mg) / 7-236 mg monomers (mean = 119 mg)

Mean difference SBP (95%CI): -2.77 (-4.72, -0.82) mm Hg, p=0.005, n=20;

Mean difference DBP (95%CI): - 2.20 (-3.46, -0.93) mm Hg, p=0.006, n=19

Meta-analysis systematic review (Hooper et al, 2012)

- 42 acute or short term chronic studies (mean 4.4 weeks, range 2-8 weeks, n=19, and one trial of 18 weeks)
- 1297 adults with or without hypertension
- Significant effect at dose ≥ 50 mg/day

Outcome	Epicatechin dose	Mean effect (95% CI) ²	No. of studies ³ (no. of participants)	I ²	P value for difference between subgroups
SBP, chronic (mm Hg)	≤ 50	0.10 (-2.20, 2.41)	6 (299)	33	0.002
	>50-100	-4.48 (-6.32, -2.63)	5 (161)	90	
	>100	-4.58 (-5.95, -3.21)	3 (110)	0	
DBP, chronic (mm Hg)	≤ 50	-0.38 (-1.97, 1.20)	6 (299)	7	0.001
	>50-100	-4.25 (-5.66, -2.85)	5 (161)	38	
	>100	-3.62 (-5.50, -1.74)	2 (78)	66	

How relevant are those effects?



On a population basis, a BP decrease of 3 mm Hg has already been recognized relevant by the FDA (antihypertensive drugs superiority)



A reduction of 2-3 mm Hg was one of the priority nutritional objective of the first (2001-2005) and second (2006-2010) French National Nutrition & Health Program



In terms of Public Health, the effects could be quite relevant!



- ✓ Endothelial dysfunction plays a major role in atherosclerotic cardiovascular disorders
- ✓ The maintenance of a normal endothelial function could be part of primary and secondary prevention of CVD
- ✓ 200mg daily cocoa flavanols have a recognized (EFSA approved; 13.5 proprietary claim) positive impact on endothelial function, vessels elasticity, and blood flow, assessed by ED-FMD
- ✓ The high flavanol cocoa extract obtained from an unique patented extraction process enables 200mg flavanols intake in small and convenient nutraceutical applications
- ✓ Cocoa flavanols are not only effective on endothelial function but also on other CV risk factors: blood pressure, glucose tolerance, insulin sensitivity, inflammation



NATUREX 

R&D team

Emilie Fromentin

Leila Falcao

Thanks to



Leen Allegaert

Herwig Bernaert

Claudine Vandemeulebroucke

Paul Arendsen



Thank you for your attention!

Visit us at www.naturex.com

NATUREX 

